A Study of WVT078 in Patients With Multiple Myeloma (MM)
Stopped early · Phase 1
Conditions studied: Multiple Myeloma (MM)
In brief
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
Key facts
- Study ID
- NCT04123418
- Run by
- Novartis Pharmaceuticals
- People needed
- 56
- Starts
- 2019-12-05
- Expected to finish
- 2024-12-02
- Last updated by the study team
- 2025-12-24
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)
You may not qualify if…
- Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment
- Malignant disease other than being treated on this study
- Active known or suspected autoimmune disease
- Impaired cardiac function or clinically significant cardiac disease
- Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter
- Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses
Where it is running
- Emory University School of Medicine-Winship Cancer Institute — Atlanta, Georgia, United States
- University Of Wisconsin — Madison, Wisconsin, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Novartis Investigative Site — Melbourne, Victoria, Australia
- Novartis Investigative Site — Dresden, Germany
- Novartis Investigative Site — Heidelberg, Germany
- Novartis Investigative Site — Tel Aviv, Israel
- Novartis Investigative Site — Milan, MI, Italy
- Novartis Investigative Site — Bunkyo Ku, Tokyo, Japan
- Novartis Investigative Site — Oslo, Norway
- Novartis Investigative Site — Santander, Cantabria, Spain
- Novartis Investigative Site — Barcelona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.